Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.

Munira BorhanyAisha ArshadHeeba QureshiRukhshanda NadeemArif JamalRaheel Ahmed Khan

Published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2024)

Our results showed that HA patients on prophylactic treatment with Emicizumab were less restricted and had improved quality of life due to marked decrease in bleeding episodes which resulted in improved health and social lives. In addition, it was well tolerated, and no participant discontinued treatment because of adverse events.

Keyphrases

healthcare
end stage renal disease
mental health
newly diagnosed
public health
chronic kidney disease
atrial fibrillation
early onset
risk assessment
climate change
health information
combination therapy
replacement therapy
drug induced